Ruboxistaurin (mesylate)

Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes[1][2][3][4].

Product Specifications

CAS Number

[192050-59-2]

Product Name Alternative

LY333531 (mesylate)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PKC

Type

Reference compound

Related Pathways

Epigenetics; TGF-beta/Smad

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ruboxistaurin-mesylate.html

Purity

99.87

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O.CS(=O)(O)=O

Molecular Formula

C29H32N4O6S

Molecular Weight

564.65

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Jirousek MR, et al. (S) -13-[ (dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3 (2H) -d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39 (14) :2664-2671.|[2]Ruboxistaurin: LY 333531. Drugs R D. 2007;8 (3) :193-199.|[3]Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1 (6) :929-35.|[4]Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41 (9) :2702-6.